TNF and osteosarcoma: We recently demonstrated that autologous PBMCs ex vivo loaded with an engineered oncolytic MYXV expressing human TNF (vMyv-hTNF) was an effective therapeutic strategy against murine K7M2 osteosarcoma cells in a lung metastatic preclinical syngeneic murine model, whereas unarmed MYXV was ineffective [13].